ArticleFrontiers in bioinformatics2026
BioGraphBench-PPI enables audit-first evaluation of negative-sampling contracts and structural baselines in protein interaction networks.
Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Biomedical graph-learning results are difficult to compare when source versions, identifier rules, data splits, structural features, and sampled-nonedge contracts are incompletely documented. Methods: We developed BioGraphBench-PPI as an audit-first benchmark for protein-protein interaction (PPI) link prediction using STRING v12.0, BioGRID 5.0.260, and two cross-resource no-overlap ablations. For each PPI task, we generated 10 predefined seeds and three balanced sampled-nonedge contracts: random, degree-matched, and two-hop. We compared local heuristics, logistic regression, random forest, histogram gradient boosting (HGB), an auditable node2vec-compatible random-walk baseline, and a two-layer GCN link-prediction baseline, reporting ranking, calibration, runtime, and confidence intervals. Results: Random sampled nonedges yielded high HGB AUPRC values (0.942-0.964), but degree-matched sampled nonedges reduced AUPRC by 0.049-0.259. The GCN baseline showed signal under random negatives in selected graphs (AUPRC 0.526-0.717) but approached chance under degree-matched and two-hop contracts (AUPRC 0.500-0.515). Discussion: BioGraphBench-PPI shows that PPI benchmark conclusions depend strongly on sampled-nonedge design and graph source. The benchmark therefore contributes an auditable evaluation contract rather than a claim that PPI prediction is solved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.